Aer Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class inhaled therapies that target mucus obstruction in chronic lung diseases. Its lead program, AER-01, is designed to break down airway mucus plugs and restore airflow in conditions such as COPD and asthma, addressing a significant unmet need not treated by current therapies.